mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA), By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others), Region and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global mRNA vaccine market is poised to grow at an impressive rate during the forecast period on account of various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, distribution, among others. Global mRNA Vaccine Market is driven by the rising incidence of cancer, genetic abnormalities, and viral infections. Approximately 10 million deaths, or nearly one in six deaths, happened due to cancer in 2020, making it one of the top causes of death globally. TAA (tumor-associated antigens), TSA (tumor-specific antigens), and their related cytokines can all be encoded and expressed by mRNA vaccines, which constitute a significant class of cancer vaccines. These vaccines are more adaptable to various diseases and patients because mRNA cancer vaccines can boost both humoral and cellular immunity. Besides, the sudden outbreak and spread of pandemic COVID-19 and the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19 is expected to create new prospects for growth of mRNA vaccine market in the coming years. This has in turn resulted many biotechnology & pharmaceutical companies and academic & research institutions come forward and start research and development and launch clinical trials for the development of different types of mRNA vaccines, thereby creating lucrative opportunities for the growth of global mRNA vaccine market during the forecast period. According to clinicaltrials.gov, around 444 clinical studies related to mRNA Vaccine are in different phases of development being conducted across different parts of the globe.

The important reason for encouraging extensive study and deployment of mRNA vaccines is their numerous distinctive benefits. One of the main causes for the development of mRNA vaccines is their convenience of production. Simple in form, its active component, RNA, is often produced in vitro utilizing linear DNA as a template. Through codon optimization, nucleoside modification, and an additional delivery method, the stability and translation efficiency of mRNA can be enhanced during this process to create a nucleic acid vaccine with high specificity and resilient stability. The vaccine's safety is another important aspect that encourages widespread use. There is no potential risk of infection or genetic damage because the mRNA does not integrate into the host genome.

mRNA vaccines create proteins that cause human bodies to generate an immune response. Since these vaccines don't involve live viruses, there is absolutely no risk of getting sick after receiving them. The body quickly breaks down mRNA, and cells don't readily take up foreign mRNA. Recent technological advancements have improved the stability of the mRNA molecule and wrapped the molecules in lipids to improve cell delivery effectiveness. These developments boost the production of spike protein on your cells, triggering a stronger immunological response.

Furthermore, owing to recent technological developments in enhanced translation, stability, and delivery methods, messenger RNAs have emerged as a promising therapeutic tool. In fact, mRNA vaccines have opened the door to new pharmacological fields and have become a significant therapeutic class. The development of vaccines is entering a new age because to these mRNA vaccines, which support next-generation vaccinations.

Industry expansion is anticipated to be supported during the projected time by increased investments in the development of cutting-edge and efficient mRNA vaccines. For instance, American mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture in April 2021 as part of a joint venture with Axcelead, Inc., and is currently building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.

The mRNA vaccine market has seen tremendous growth in recent years, but there are still several challenges facing the market globally. These challenges include the high cost of production, storage and transportation requirements, regulatory challenges, intellectual property rights, and vaccine hesitancy. The regulatory environment for mRNA vaccines is complex and presents significant challenges to the market. The development and approval of mRNA vaccines require rigorous clinical trials and regulatory processes, which can be time-consuming and expensive. The regulatory requirements vary from country to country, which can create further challenges in the distribution and use of mRNA vaccines globally.

Advantages of mRNA Vaccines

The mRNA vaccine market has seen tremendous growth in recent years, largely due to the advantages of mRNA vaccines. mRNA vaccines offer several benefits over traditional vaccines, and their potential applications have spurred investment and development in the market. One of the primary advantages of mRNA vaccines is their rapid development timeline. Traditional vaccine development can take several years, while mRNA vaccines can be developed in a matter of weeks or months. This rapid development timeline is crucial in the fight against pandemics and emerging infectious diseases, where fast response times can mean the difference between life and death. The rapid development of mRNA vaccines has also made them attractive to investors and pharmaceutical companies, driving growth in the mRNA vaccine market. The ability to quickly develop vaccines for new and emerging diseases has opened up new market opportunities and spurred investment in the development and production of mRNA vaccines.

mRNA vaccines have also demonstrated high efficacy in clinical trials. For example, the Pfizer-BioNTech and Moderna COVID-19 vaccines have shown to be up to 95% effective in preventing COVID-19 infections. The high efficacy of mRNA vaccines is due to their ability to trigger a robust immune response by instructing cells to produce specific proteins that stimulate the immune system. The high efficacy of mRNA vaccines has been a significant factor in their widespread adoption, driving demand and growth in the mRNA vaccine market. As more vaccines are developed and proven effective, demand for mRNA vaccines is likely to continue to grow.

Another advantage of mRNA vaccines is their easy modification. mRNA vaccines can be easily modified to target different diseases, strains, or variants of the same disease. This flexibility allows for the development of vaccines that can quickly adapt to new and emerging diseases. The ability to easily modify mRNA vaccines has made them an attractive option for investors and pharmaceutical companies, spurring growth in the mRNA vaccine market. As more vaccines are developed and proven effective, demand for mRNA vaccines is likely to continue to grow.

mRNA vaccines are safesssssssssssss and well-tolerated, with few reported adverse effects. This safety profile is since mRNA vaccines do not contain live or weakened viruses, and the mRNA sequences are rapidly degraded by the body after they have triggered an immune response. The safety profile of mRNA vaccines has been a significant factor in their widespread adoption, driving demand and growth in the mRNA vaccine market. As more vaccines are developed and proven safe, demand for mRNA vaccines is likely to continue to grow.

mRNA vaccines have the potential to usher in a new era of personalized medicine. Since mRNA vaccines can be easily modified to target specific genetic sequences, they could be used to treat genetic disorders or other diseases caused by specific genetic mutations. This potential application could revolutionize the treatment of genetic diseases and create new market opportunities in the mRNA vaccine market. As technology continues to advance, it is likely that mRNA vaccines will play an increasingly important role in the future of medicine and continue to influence the growth of the mRNA vaccine market.

Increasing Research Activities to produce mRNA-based Vaccines

The numerous benefits mRNA offers over other therapeutic modalities, such as higher biological efficacy, enhanced potent immunogenicity, and versatile delivery platforms at low toxicity levels, are the main drivers of the ongoing research and development efforts being made in this field. The development of mRNA-based vaccines to prevent infectious or chronic diseases like diabetes, HIV, cancer, and cardiovascular diseases is the subject of extensive research. There are currently 430 clinical trials using mRNA vaccines to prevent diseases other than COVID-19. The majority of these clinical trials, according to an analysis by Clinicaltrials.gov, are conducted in the United States.

A multivalent, mRNA-based vaccine that protects against all 20 known influenza virus subtypes has been created by researchers at the Perelman School of Medicine at the University of Pennsylvania. They take a different approach from earlier attempts to create a universal flu vaccine by including antigens unique to each subtype rather than just a smaller set of antigens shared by subtypes. The SARS-CoV-2 vaccines made by Pfizer and Moderna used the same mRNA technology as this strategy. Penn was a leader in the development of the mRNA technology used in those COVID-19 vaccines.


Download Free Sample Report

Market Segmentation

Global mRNA Vaccine Market can be segmented by mRNA type, by application and by region. Based on mRNA type, the market can be divided into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA. Based on application the market is divided into COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, and others. Regionally, the mRNA Vaccine can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc., are some of the leading players operating in the Global mRNA Vaccine Market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         By mRNA Type

·         By Application

·         By Region

Regional scope

North America, Europe, Asia Pacific, South America, Middle East & Africa

Key companies profiled

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Global mRNA Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global mRNA Vaccine Market, By mRNA Type:

o    Nucleoside-modified mRNA

o    Unmodified mRNA

o    Self-Amplifying mRNA

  • Global mRNA Vaccine Market, By Application:

o    COVID-19 mRNA Vaccines

o    Non COVID-19 mRNA Vaccines

o    Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global mRNA Vaccine Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global mRNA Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.           Markets Covered

1.2.2.           Years Considered for Study

1.2.3.           Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Clinical Trial Analysis

4.1.  Ongoing Clinical Trials

4.2.  Completed Clinical Trials

4.3.  Terminated Clinical Trials

4.4.  Breakdown of Pipeline, By Development Phase

4.5.  Breakdown of Pipeline, By Status

4.6.  Breakdown of Pipeline, By Study Type

4.7.  Breakdown of Pipeline, By Region

4.8.  Clinical Trials Heat Map

5.    Voice of Customer

6.    Global mRNA Vaccine Market Outlook

6.1.  Market Size & Forecast

6.1.1.           By Value

6.2.  Market Share & Forecast

6.2.1.           By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

6.2.2.           By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

6.2.3.           By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

6.2.4.           By Company (2022)

6.3.  Product Map

6.3.1.           By mRNA Type

6.3.2.           By Application

6.3.3.           By Region

7.    North America mRNA Vaccine Market Outlook

7.1.  Market Size & Forecast          

7.1.1.           By Value

7.2.  Market Share & Forecast

7.2.1.           By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

7.2.2.           By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

7.2.3.           By Country

7.3.  North America: Country Analysis

7.3.1.           United States mRNA Vaccine Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By mRNA Type

7.3.1.2.2.             By Application

7.3.2.           Canada mRNA Vaccine Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By mRNA Type

7.3.2.2.2.             By Application

7.3.3.           Mexico mRNA Vaccine Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By mRNA Type

7.3.3.2.2.             By Application

8.    Europe mRNA Vaccine Market Outlook

8.1.  Market Size & Forecast          

8.1.1.           By Value

8.2.  Market Share & Forecast

8.2.1.           By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

8.2.2.           By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

8.2.3.           By Country

8.3.  Europe: Country Analysis

8.3.1.           France mRNA Vaccine Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By mRNA Type

8.3.1.2.2.             By Application

8.3.2.           Germany mRNA Vaccine Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By mRNA Type

8.3.2.2.2.             By Application

8.3.3.           United Kingdom mRNA Vaccine Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By mRNA Type

8.3.3.2.2.             By Application

8.3.4.           Italy mRNA Vaccine Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By mRNA Type

8.3.4.2.2.             By Application

8.3.5.           Spain mRNA Vaccine Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By mRNA Type

8.3.5.2.2.             By Application

9.    Asia-Pacific mRNA Vaccine Market Outlook

9.1.  Market Size & Forecast          

9.1.1.           By Value

9.2.  Market Share & Forecast

9.2.1.           By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

9.2.2.           By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

9.2.3.           By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.           China mRNA Vaccine Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By mRNA Type

9.3.1.2.2.             By Application

9.3.2.           India mRNA Vaccine Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By mRNA Type

9.3.2.2.2.             By Application

9.3.3.           Japan mRNA Vaccine Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By mRNA Type

9.3.3.2.2.             By Application

9.3.4.           South Korea mRNA Vaccine Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By mRNA Type

9.3.4.2.2.             By Application

9.3.5.           Australia mRNA Vaccine Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By mRNA Type

9.3.5.2.2.             By Application

10.  South America mRNA Vaccine Market Outlook

10.1.              Market Size & Forecast

10.1.1.         By Value

10.2.              Market Share & Forecast

10.2.1.         By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

10.2.2.         By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

10.2.3.         By Country

10.3.              South America: Country Analysis

10.3.1.         Brazil mRNA Vaccine Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By mRNA Type

10.3.1.2.2.           By Application

10.3.2.         Argentina mRNA Vaccine Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By mRNA Type

10.3.2.2.2.           By Application

10.3.3.         Colombia mRNA Vaccine Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By mRNA Type

10.3.3.2.2.           By Application

11.  Middle East and Africa mRNA Vaccine Market Outlook

11.1.              Market Size & Forecast

11.1.1.         By Value

11.2.              Market Share & Forecast

11.2.1.         By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)

11.2.2.         By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)

11.2.3.         By Country

11.3.              MEA: Country Analysis

11.3.1.         South Africa mRNA Vaccine Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By mRNA Type

11.3.1.2.2.           By Application

11.3.2.         Saudi Arabia mRNA Vaccine Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By mRNA Type

11.3.2.2.2.           By Application

11.3.3.         UAE mRNA Vaccine Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By mRNA Type

11.3.3.2.2.           By Application

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Merger Acquisition

13.3.              Product launches

14.  Global mRNA Vaccine Market: SWOT Analysis

15.  Porter’s Five Forces Analysis

15.1.              Competition in the Industry

15.2.              Potential of New Entrants

15.3.              Power of Suppliers

15.4.              Power of Customers

15.5.              Threat of Substitute Products

16.  Competitive Landscape

16.1.              Business Overview

16.2.              Product Offerings

16.3.              Recent Developments

16.4.              Financials (As Reported)

16.5.              Key Personnel

16.6.              SWOT Analysis

15.6.1.  Arcturus Therapeutics Holdings Inc.

15.6.2.  BioNTech SE

15.6.3.  CureVac N.V.

15.6.4.  Daiichi Sankyo Company Limited.

15.6.5.  Ethris GmbH

15.6.6.  GlaxoSmithKline plc

15.6.7.  Gennova Biopharmaceuticals Ltd

15.6.8.  Moderna, Inc.

15.6.9.  Pantherna Therapeutics GmbH

15.6.10.             Providence Therapeutics

15.6.11.             Silence Therapeutics

15.6.12.             Translate Bio

15.6.13.             VERSAMEB AG

15.6.14.             Verve Therapeutics Inc.

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Numerous advantages over the other nucleic acid-based vaccines, rapidly producing and inexpensive, increasing research activities on the development of mRNA vaccines for various chronic disease, advancement in the service industry, are some of factors driving the growth of Global mRNA Vaccine Market.

down-arrow

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc. are some of the leading players operating in the Global mRNA Vaccine Market.

down-arrow

Self-Amplifying mRNA is expected to see growth during the forecast period owing to their high potential and cost effectiveness.

down-arrow

North America region will face significant growth in the market of mRNA Vaccine Market due to the presence of prominent players dealing in mRNA Vaccine in United States.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

mRNA Vaccines Market to be dominated by the Non-COVID-19 rRNA Vaccine through 2028

Dec, 2022

Rising incidence of chronic and infectious diseases is expected to drive the growth of Global mRNA Vaccine Market in the forecast period.

Why Choose Us